Medidata Co-Founder Says Future Trends Explain Logic For Buying SHYFT Analytics
Medidata president says buying SHYFT Analytics creates unified trial, commercialization data platform for life sciences sector, offering reduced risk, faster drug development, better outcomes.
You may also be interested in...
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.